MediWound Ltd. Ordinary Shares (MDWD)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, with durable earnings and a margin of safety. MediWound is understandable in outline: it markets NexoBrid for burn eschar removal and is developing EscharEx. But the figures show a very small commercial base and heavy losses. In fiscal Q2 2026, the period reported as 2026-Q2, revenue was $3.1 million and net income was negative $7.4 million, a negative 239.07% margin. Trailing free cash flow was negative $28.5 million, a -13.5% free cash flow yield on a $210.6 million market cap. FairStock's calculated return measures are poor: ROE -72.37% and ROCE -28.59%. The Piotroski F-Score is 1/9, indicating weak fundamental momentum. Debt/equity is 0.24, so leverage is not the main problem; the main problem is cash burn and lack of profitability. At the 2026-10-13 close of $12.22, P/B is 4.43, and the stock sits near the bottom of its 52-week range of $12.19 to $20.03. A low beta of 0.14 and an Altman Z-Score of 3.50 are not enough to offset negative earnings and cash flow. FairStock Score 21/100, and no Lynch category applies because only 0 years of filed results are available versus the 3 years needed. I see no demonstrated moat or margin of safety in these numbers. The company could be a pipeline option, but as a value investment it is speculative and currently unprofitable.

In plain English: MediWound is a small healthcare company that sells a burn-treatment product called NexoBrid and is developing another product called EscharEx. The business looks weak right now: in the quarter reported as 2026-Q2, revenue was $3.1 million and it lost $7.4 million. At the 2026-10-13 closing price of $12.22, the shares look expensive against those weak current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer